{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:12:23Z","timestamp":1792811543361,"version":"4.5.0"},"reference-count":75,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,12,7]],"date-time":"2018-12-07T00:00:00Z","timestamp":1544140800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"DOI":"10.3389\/fneur.2018.01067","type":"journal-article","created":{"date-parts":[[2018,12,6]],"date-time":"2018-12-06T23:16:28Z","timestamp":1544138188000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":92,"title":["Pharmacokinetic Interactions of Clinical Interest Between Direct Oral Anticoagulants and Antiepileptic Drugs"],"prefix":"10.3389","volume":"9","author":[{"given":"Alessandro","family":"Galgani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Palleria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi Francesco","family":"Iannone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovambattista","family":"De Sarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo Sean","family":"Giorgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Maschio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,12,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur Heart J."},{"key":"B2","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s11239-017-1607-9","article-title":"Efficacy and safety of outpatient treatment with direct oral anticoagulation in pulmonary embolism","volume":"45","author":"Ghazvinian","year":"2018","journal-title":"J Thrombosis Thrombolysis"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1212\/WNL.0000000000004407","article-title":"Incidence and management of seizures after ischemic stroke","volume":"89","author":"Wang","year":"2017","journal-title":"Neurology"},{"key":"B4","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1007\/s40266-013-0119-3","article-title":"Concerns about the use of new oral anticoagulants for stroke prevention in elderly patients with atrial fibrillation","volume":"30","author":"St\u00f6llberger","year":"2013","journal-title":"Drugs Aging"},{"key":"B5","doi-asserted-by":"publisher","first-page":"18024","DOI":"10.1038\/nrdp.2018.24","article-title":"Epilepsy","volume":"4","author":"Devinsky","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"B6","doi-asserted-by":"publisher","first-page":"9S","DOI":"10.1177\/1076029609343004","article-title":"Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor","volume":"15","author":"Stangier","year":"2009","journal-title":"Clin Appl Thromb Hemost."},{"key":"B7","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s40262-015-0267-1","article-title":"Impact of genetic polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on drug disposition and potential clinical implications: update of the literature","volume":"54","author":"Wolking","year":"2015","journal-title":"Clin Pharmacokinet."},{"key":"B8","doi-asserted-by":"publisher","first-page":"622","DOI":"10.2174\/1389200218666170427113504","article-title":"Dabigatran\u2014metabolism, pharmacologic properties and drug interactions","volume":"18","author":"Antonijevic","year":"2017","journal-title":"Curr Drug Metab."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1080\/17425255.2016.122503","article-title":"Drug-drug interactions of non-vitamin K oral anticoagulants","volume":"12","author":"Voukalis","year":"2016","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1111\/j.1365-2125.2012.04453.x","article-title":"Oral bioavailability of dabigatran etexilate (Pradaxa\u00ae) after co-medication with verapamil in healthy subjects","volume":"75","author":"H\u00e4rtter","year":"2013","journal-title":"Br J Clin Pharmacol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1124\/jpet.111.180240","article-title":"In vitro and in vivo P-glycoprotein transport characteristics of rivaroxaban","volume":"338","author":"Gnoth","year":"2011","journal-title":"J Pharmacol Exp Therapeut."},{"key":"B12","doi-asserted-by":"publisher","first-page":"609","DOI":"10.2174\/1389200218666170424151551","article-title":"Apixaban\u2014Metabolism, pharmacologic properties and drug interactions","volume":"18","author":"Kubisz","year":"2017","journal-title":"Curr Drug Metab."},{"key":"B13","doi-asserted-by":"publisher","first-page":"636","DOI":"10.2174\/1389200218666170518165443","article-title":"Rivaroxaban\u2014Metabolism, pharmacologic properties and drug interactions","volume":"18","author":"Kvasnicka","year":"2017","journal-title":"Curr Drug Metab."},{"key":"B14","doi-asserted-by":"publisher","first-page":"117","DOI":"10.2146\/ajhp150821","article-title":"Edoxaban: a direct oral anticoagulant","volume":"74","author":"Poulakos","year":"2017","journal-title":"Am J Heal Pharm."},{"key":"B15","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1161\/ATVBAHA.110.202978","article-title":"Rivaroxaban: a new oral factor Xa inhibitor","volume":"30","author":"Perzborn","year":"2010","journal-title":"Arteriosclerosis Thrombosis Vascular Biol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1477-9560-11-10","article-title":"Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring","volume":"11","author":"Mueck","year":"2013","journal-title":"Thrombosis J."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1124\/dmd.108.025569","article-title":"Metabolism and excretion of rivaroxaban, an oral, direct factor xa inhibitor, in rats, dogs, and humans","volume":"37","author":"Weinz","year":"2009","journal-title":"Drug Metab Disposit."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1124\/dmd.112.046888","article-title":"Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans","volume":"40","author":"Bathala","year":"2012","journal-title":"Drug Metab Disposit."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1080\/17425255.2018.1530213","article-title":"Pharmacokinetics of new oral anticoagulants: implications for use in routine care","volume":"14","author":"Ingrasciotta","year":"2018","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1684\/epd.2014.0714","article-title":"Interactions between antiepileptic drugs, and between antiepileptic drugs and other drugs","volume":"16","author":"Zaccara","year":"2014","journal-title":"Epileptic Disord"},{"key":"B21","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1007\/s40262-013-0087-0","article-title":"Drug interactions with the newer antiepileptic drugs (AEDs)\u2014Part 1: pharmacokinetic and pharmacodynamics interactions between AEDs","volume":"52","author":"Patsalos","year":"2013","journal-title":"Clin Pharmacokinet."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1007\/s40262-013-0088-z","article-title":"Drug interactions with the newer antiepileptic drugs (AEDs)\u2014Part 2: pharmacokinetic and pharmacodynamics interactions between AEDs and drugs used to treat non-epilepsy disorders","volume":"52","author":"Patsalos","year":"2013","journal-title":"Clin Pharmacokinet."},{"key":"B23","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1111\/j.1365-2125.2005.02529.x","article-title":"Clinically relevant drug interactions with antiepileptic drugs","volume":"61","author":"Perucca","year":"2006","journal-title":"Br J Clin Pharmacol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/j.1365-2125.2005.02539.x","article-title":"The pharmacokinetic and pharmacodynamic consequences of the co-administration of lamotrigine and a combined oral contraceptive in healthy female subjects","volume":"61","author":"Sidhu","year":"2006","journal-title":"Br J Clin Pharmacol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1097\/FTD.0b013e31815c16f5","article-title":"Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P4503A4 and the role of therapeutic drug monitoring","volume":"29","author":"Zhou","year":"2007","journal-title":"Ther Drug Monit."},{"key":"B26","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S1474-4422(03)00409-5","article-title":"Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs","volume":"2","author":"Patsalos","year":"2003","journal-title":"Lancet Neurol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/S1474-4422(03)00483-6","article-title":"Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs","volume":"2","author":"Patsalos","year":"2003","journal-title":"Lancet Neurol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/epi.12865","article-title":"The clinical pharmacology profile of the new antiepileptic drug perampanel: a novel noncompetitive AMPA receptor antagonist","volume":"56","author":"Patsalos","year":"2015","journal-title":"Epilepsia"},{"key":"B29","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1046\/j.1528-1157.2002.13001.x","article-title":"The importance of drug interactions in epilepsy therapy","volume":"43","author":"Patsalos","year":"2002","journal-title":"Epilepsia"},{"key":"B30","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1586\/ern.09.136","article-title":"Drug interactions involving the new second- and third-generation antiepileptic drugs","volume":"10","author":"Johannessen","year":"2010","journal-title":"Expert Rev Neurother."},{"key":"B31","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.addr.2011.12.003","article-title":"The transport of antiepileptic drugs by P-glycoprotein","volume":"64","author":"Zhang","year":"2012","journal-title":"Adv Drug Deliv Rev."},{"key":"B32","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.1476-5381.2011.01557.x","article-title":"Interactions between antidepressants and P-glycoprotein at the blood-brain barrier: clinical significance of in vitro and in vivo findings","volume":"165","author":"O'Brien","year":"2012","journal-title":"Br J Pharmacol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1007\/s40263-012-0008-z","article-title":"Psychotropic drug-drug interactions involving P-glycoprotein","volume":"26","author":"Akamine","year":"2012","journal-title":"CNS Drugs"},{"key":"B34","unstructured":"Zonisamide. Summary of Product Characteristics2017"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1111\/j.1528-1167.2011.03140.x","article-title":"In vitro transport profile of carbamazepine, oxcarbazepine, eslicarbazepine acetate, and their active metabolites by human P-glycoprotein","volume":"52","author":"Zhang","year":"2011","journal-title":"Epilepsia"},{"key":"B36","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/S0304-3940(02)00423-8","article-title":"P-Glycoprotein-mediated efflux of phenobarbital, lamotrigine, and felbamate at the blood-brain barrier: evidence from microdialysis experiments in rats","volume":"327","author":"Potschka","year":"2002","journal-title":"Neurosci Lett."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1517\/17425255.2014.956081","article-title":"Pharmacokinetic and pharmacodynamic interactions between antiepileptics and antidepressants","volume":"10","author":"Italiano","year":"2014","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.ejphar.2013.03.049","article-title":"Impact of P-glycoprotein and breast cancer resistance protein on the brain distribution of antiepileptic drugs in knockout mouse models","volume":"710","author":"Nakanishi","year":"2013","journal-title":"Eur J Pharmacol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/j.1528-1167.2006.00414.X","article-title":"Influence of lamotrigine and topiramate on MDR1 expression in difficult-to-treat temporal lobe epilepsy","volume":"47","author":"Wang-Tilz","year":"2006","journal-title":"Epilepsia"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1080\/17512433.2016.1254041","article-title":"A pharmacological overview of lamotrigine for the treatment of epilepsy","volume":"9","author":"Yasam","year":"2016","journal-title":"Expert Rev Clin Pharmacol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.eplepsyres.2010.12.013","article-title":"Antiepileptic drugs modulate P-glycoproteins in the brain: a mice study with11C-desmethylloperamide","volume":"94","author":"Moerman","year":"2011","journal-title":"Epilepsy Res."},{"key":"B42","doi-asserted-by":"publisher","first-page":"192","DOI":"10.3389\/fneur.2013.00192","article-title":"Clinical pharmacology and pharmacokinetics of levetiracetam","volume":"4","author":"Wright","year":"2013","journal-title":"Front Neurol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.2165\/00003088-200342120-0000","article-title":"Clinical pharmacokinetics of oxcarbazepine","volume":"42","author":"May","year":"2003","journal-title":"Clin Pharmacokinet."},{"key":"B44","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1111\/bcp.12951","article-title":"Impact of perampanel on pharmacokinetics of concomitant antiepileptics in patients with partial-onset seizures: pooled analysis of clinical trials","volume":"82","author":"Majid","year":"2016","journal-title":"Br J Clin Pharmacol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1517\/17425255.2013.749239","article-title":"Pharmacokinetic and pharmacodynamic profile of pregabalin and its role in the treatment of epilepsy","volume":"9","author":"Schulze-Bonhage","year":"2013","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/j.0013-9580.2004.455003.x","article-title":"Pregabalin pharmacology and its relevance to clinical practice","volume":"45","author":"Ben-Menachem","year":"2004","journal-title":"Epilepsia"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1111\/j.1528-1167.2008.01665.x","article-title":"Rufinamide: clinical pharmacokinetics and concentrationresponse relationships in patients with epilepsy","volume":"49","author":"Perucca","year":"2008","journal-title":"Epilepsia"},{"key":"B48","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/S0009-9236(97)90044-8","article-title":"Influence of stiripentol on cytochrome P450-mediated metabolic pathways in humans: in vitro and in vivo comparison and calculation of in vivo inhibition constants","volume":"62","author":"Tran","year":"1997","journal-title":"Clin Pharmacol Ther."},{"key":"B49","doi-asserted-by":"publisher","first-page":"D237","DOI":"10.1093\/nar\/gkp970","article-title":"SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions","volume":"38","author":"Preissner","year":"2010","journal-title":"Nucleic Acids Res."},{"key":"B50","doi-asserted-by":"publisher","first-page":"763","DOI":"10.2165\/00003088-200443120-00001","article-title":"Pharmacokinetic interactions of topiramate","volume":"43","author":"Bialer","year":"2004","journal-title":"Clin Pharmacokinet."},{"key":"B51","unstructured":"Lacosamide. Summary of Product Characteristics2013"},{"key":"B52","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s40262-015-0276-0","article-title":"Clinical pharmacokinetic and pharmacodynamic profile of lacosamide","volume":"54","author":"Cawello","year":"2015","journal-title":"Clin Pharmacokinet."},{"key":"B53","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.seizure.2004.04.016","article-title":"Zonisamide: chemistry, mechanism of action, and pharmacokinetics","volume":"13","author":"Leppik","year":"2004","journal-title":"Seizure"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1111\/j.1476-5381.2009.00634.x","article-title":"Combined effects of epileptic seizure and phenobarbital induced overexpression of P-glycoprotein in brain of chemically kindled rats","volume":"159","author":"Jing","year":"2010","journal-title":"Br J Pharmacol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.phrs.2016.02.014","article-title":"Clinically significant pharmacokinetic drug interactions of antiepileptic drugs with new antidepressants and new antipsychotics","volume":"106","author":"Spina","year":"2016","journal-title":"Pharmacol Res."},{"key":"B56","doi-asserted-by":"publisher","first-page":"946","DOI":"10.2165\/11539230-000000000-00000","article-title":"Chronic administration of phenytoin induces efflux transporter overexpression in rats","volume":"66","author":"Alvariza","year":"2014","journal-title":"Pharmacol Rep."},{"key":"B57","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.clpt.2004.04.011","article-title":"Carbamazepine regulates intestinal P-glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans","volume":"76","author":"Giessmann","year":"2004","journal-title":"Clin Pharmacol Ther."},{"key":"B58","doi-asserted-by":"publisher","first-page":"765","DOI":"10.3109\/00498254.2015.1118774","article-title":"Evaluation of cytochrome P450 inductions by anti-epileptic drug oxcarbazepine, 10-hydroxyoxcarbazepine, and carbamazepine using human hepatocytes and HepaRG cells","volume":"46","author":"Sugiyama","year":"2016","journal-title":"Xenobiotica"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1038\/sj.leu.2403390","article-title":"Valproic acid inhibits proliferation and induces apoptosis in acute myeloid leukemia cells expressing P-gp and MRP1","volume":"18","author":"Tang","year":"2004","journal-title":"Leukemia"},{"key":"B60","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1038\/sj.bjp.0706830","article-title":"The antiepileptic and anticancer agent, valproic acid, induces P-glycoprotein in human tumour cell lines and in rat liver","volume":"149","author":"Eyal","year":"2006","journal-title":"Br J Pharmacol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1124\/dmd.106.014456","article-title":"Valproic acid induces CYP3A4 and MDR1 gene expression by activation of constitutive androstane receptor and pregnane X receptor pathways","volume":"35","author":"Cerveny","year":"2007","journal-title":"Drug Metab Dispos."},{"key":"B62","doi-asserted-by":"publisher","first-page":"788","DOI":"10.4081\/cp.2015.788","article-title":"Left atrial appendage thrombosis during therapy with rivaroxaban in elective cardioversion for permanent atrial fibrillation","volume":"5","author":"Serra","year":"2015","journal-title":"Clin Pract."},{"key":"B63","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s40268-014-0045-9","article-title":"Correlation between trough plasma dabigatran concentrations and estimates of glomerular filtration rate based on creatinine and cystatin C","volume":"14","author":"Chin","year":"2014","journal-title":"Drugs R D"},{"key":"B64","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1177\/1060028018759938","article-title":"Management of phenobarbital and apixaban interaction in recurrent cardioembolic stroke","volume":"52","author":"King","year":"2018","journal-title":"Ann Pharmacother."},{"key":"B65","doi-asserted-by":"publisher","first-page":"4760612","DOI":"10.1155\/2017\/4760612","article-title":"Decreased rivaroxaban levels in a patient with cerebral vein thrombosis receiving phenytoin","volume":"2017","author":"Becerra","year":"2017","journal-title":"Case Rep Hematol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1001\/jama.2017.13883","article-title":"Association between use of non-vitamin K oral anticoagulants with and without concurrent medications and risk of major bleeding in nonvalvular atrial fibrillation","volume":"318","author":"Chang","year":"2017","journal-title":"Am Med Assoc."},{"key":"B67","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.1002\/phar.1698","article-title":"Reduced anticoagulant effect of dabigatran in a patient receiving concomitant phenytoin","volume":"36","author":"Wiggins","year":"2016","journal-title":"Pharmacother Publ."},{"key":"B68","doi-asserted-by":"publisher","first-page":"554.e13","DOI":"10.1016\/j.cjca.2016.10.022","article-title":"Development of left atrial thrombus after coadministration of dabigatran etexilate and phenytoin","volume":"33","author":"Hager","year":"2017","journal-title":"Can J Cardiol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"e247","DOI":"10.1016\/j.amjmed.2016.06.017","article-title":"Measurement of dabigatran drug levels to manage patients taking interacting drugs: a case report","volume":"129","author":"Laureano","year":"2016","journal-title":"Am J Med."},{"key":"B70","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.pjnns.2017.01.010","article-title":"Recurrent venous thrombosis under rivaroxaban and carbamazepine for symptomatic epilepsy","volume":"51","author":"St\u00f6llberger","year":"2017","journal-title":"Neurol Neurochir Pol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"103","DOI":"10.7861\/clinmedicine.18-1-103","article-title":"Pulmonary embolism in a patient on rivaroxaban and concurrent carbamazepine","volume":"18","author":"Burden","year":"2018","journal-title":"Clin Med."},{"key":"B72","first-page":"A6568","article-title":"Pulmonary embolism due to interaction between rivaroxaban and carbamazepine","volume":"157","author":"Risselada","year":"2013","journal-title":"Ned Tijdschr Geneeskd."},{"key":"B73","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.hrtlng.2014.03.004","article-title":"Prolonged anticoagulant activity of rivaroxaban in a polymorbid elderly female with non-convulsive epileptic state","volume":"43","author":"Stollberger","year":"2014","journal-title":"Heart Lung"},{"key":"B74","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1093\/ehjcvp\/pvw032","article-title":"Non-vitamin-K oral anticoagulants and laboratory testing: now and in the future: views from a workshop at the European Medicines Agency (EMA)","volume":"3","author":"Salmonson","year":"2017","journal-title":"Eur Heart J Cardiovasc Pharmacother."},{"key":"B75","doi-asserted-by":"publisher","first-page":"6","DOI":"10.21037\/atm.2017.01.03","article-title":"Laboratory monitoring of direct oral anticoagulants (DOACs)-The perfect storm?","volume":"5","author":"Lippi","year":"2017","journal-title":"Ann Transl Med."}],"updated-by":[{"DOI":"10.3389\/fneur.2019.01381","type":"corrigendum","label":"Corrigendum","source":"publisher","updated":{"date-parts":[[2020,1,29]],"date-time":"2020-01-29T00:00:00Z","timestamp":1580256000000}}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fneur.2018.01067\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,29]],"date-time":"2020-01-29T01:26:32Z","timestamp":1580261192000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fneur.2018.01067\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,7]]},"references-count":75,"alternative-id":["10.3389\/fneur.2018.01067"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2018.01067","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,7]]},"article-number":"1067"}}